Papa Murphy's Holdings Inc (NASDAQ: FRSH) gained 20 percent to $17.40 in the extended session after the company said fourth-quarter same-store sales grew 8.4 percent. The company forecast the measure will grow 3 percent in fiscal 2015.
Wix.Com Ltd (NASDAQ: WIX) rose 9 percent to $19.25. The Israeli-based Web development platform provider raised its outlook for the first quarter and full year.
Akorn, Inc. (NASDAQ: AKRX) picked up 7 percent to $47.10 after the company filed its Form 10-K for the year ended December 31, 2014, along with re-stated results for the first and second quarters.
Oracle Corporation (NYSE: ORCL) increased 2 percent in Tuesday's extended session to $43.52 after the company met Wall Street's expectations for third-quarter results.
Esperion Therapeutics Inc (NASDAQ: ESPR) gave back a little of its earlier gains after hours. The company closed up more than 29 percent on favorable news concerning its potential cholesterol drug, but changed hands recently at $97.35, off $2.25.
Nektar Therapeutics (NASDAQ: NKTR) plunged more than 16 percent to $11.80 after the company said its breast cancer treatment failed to produce significant results for the primary end point in a Phase III trial.
RSP Permian Inc (NYSE: RSPP) declined 4 percent to $25.99 in the extended session Tuesday after the company announced a public offering of five million shares by the company and 4 million shares by certain selling stockholders.
Anthera Pharmaceuticals Inc (NASDAQ: ANTH) fell 9 percent to $4.76 after the company announced a stock offering of undetermined size to raise capital for research and development. The company said Monday it will continue a Phase III trial of its kidney disease treatment.
Five Prime Therapeutics Inc (NASDAQ: FPRX) dropped 7 percent to $24 in extended trading after the company posted fourth-quarter earnings.
See more from Benzinga
- RBC: Seagate Technology 'Oversold' In Light Of Dividend Yield
- Analysts See Biogen Catalyst Coming On Friday
- Pricing Woes May Hurt Q2 For Micron Technology
© 2015 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.